Edition:
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

28.36USD
23 Sep 2016
Change (% chg)

$-0.38 (-1.32%)
Prev Close
$28.74
Open
$28.70
Day's High
$28.86
Day's Low
$28.19
Volume
319,535
Avg. Vol
675,225
52-wk High
$41.91
52-wk Low
$25.51

Latest Key Developments (Source: Significant Developments)

Pharmathene says "protests" Dept of Health and Human Services anthrax vaccine solicitation
Friday, 5 Aug 2016 12:56pm EDT 

Pharmathene Inc: "Formal protest" against Department of Health and Human Services, challenging solicitation for "next-generation anthrax vaccine provider" . As per complaint, government's "request for proposals" written in a way that assures source award to Emergent Biosolutions, which makes anthrax vaccine ."Protest requests GAO suspend award under solicitation while it reviews Pharmathene's complaint".  Full Article

Emergent BioSolutions Q2 GAAP loss per share $0.27
Thursday, 4 Aug 2016 04:15pm EDT 

Emergent Biosolutions Inc : Emergent BioSolutions reports second quarter and six months 2016 financial results . Q2 revenue $101.5 million versus i/b/e/s view $111.2 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.27 .Will continue to temporarily postpone its financial guidance for 2016 until further clarity is reached U.S. Government contracts.  Full Article

Emergent BioSolutions says "when issued" trading of Aptevo stock to start today
Wednesday, 20 Jul 2016 07:00am EDT 

Emergent Biosolutions Inc : Aptevo common stock will commence trading today, July 20, 2016, on a "when issued" basis under symbol "APVOV" on NASDAQ global select market . Emergent BioSolutions announces commencement of when issued trading of Aptevo common stock .Expects that dividend distribution will be paid on August 1, 2016.  Full Article

Emergent Biosolutions to repurchase shares for up to $50 mln
Friday, 15 Jul 2016 07:00am EDT 

Emergent Biosolutions Inc : Emergent Biosolutions to implement stock repurchase program for up to $50 million of its common stock . Repurchase program will be funded using company's working capital. . As of March 31, 2016, company had cash and cash equivalents of approximately $341 million. .Term of board authorization of repurchase program is until December 31, 2017..  Full Article

Emergent BioSolutions' board approves spin-off of Aptevo Therapeutics
Monday, 11 Jul 2016 07:00am EDT 

Emergent BioSolutions Inc. : Emergent Biosolutions' Board Of Directors Approves Spin Off of Aptevo Therapeutics and sets record and dividend distribution dates and distribution ratio . Expects to complete distribution of aptevo common stock to emergent stockholders on august 1, 2016. . Aptevo expects its common stock to begin trading on a "when issued" basis shortly before july 22, 2016 record date under ticker "apvo wi." . Aptevo has applied for listing on nasdaq global market. . On august 1, 2016, aptevo common stock is expected to begin "regular way" trading on nasdaq under symbol "apvo." .Emergent will continue to trade on new york stock exchange under ticker symbol "ebs.".  Full Article

Emergent BioSolutions says FDA completed pre-approval inspection of manufacturing facility for BioThrax
Tuesday, 21 Jun 2016 07:00am EDT 

Emergent BioSolutions Inc : Approval inspection of Emergent BioSolutions' large-scale manufacturing facility for BioThrax . Company received a no action indicated decision and no form 483 observations. .SBLA has a prescription drug user fee act (PDUFA) target action date of August 15, 2016.  Full Article

FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55
Friday, 17 Jun 2016 07:00am EDT 

Emergent Biosolutions : FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016 .FDA Accepts Emergent Biosolutions' Supplemental Biologics License Application For Large-Scale manufacturing of biothrax in building 55.  Full Article

Emergent Biosolutions Inc receives FDA orphan drug status for BioThrax
Wednesday, 15 Jun 2016 07:00am EDT 

Emergent BioSolutions Inc : Emergent BioSolutions Inc receives FDA orphan drug status for BioThrax for post-exposure prophylaxis of anthrax disease .Orphan drug status provides market exclusivity through November 2022, representing 7 years from date FDA approved pep indication for BioThrax.  Full Article

Emergent BioSolutions Inc gives FY 2016 outlook
Monday, 11 Jan 2016 07:01am EST 

Emergent BioSolutions Inc:Expects FY 2016 total revenues of $600 mln to $630 mln.Expects FY 2016 GAAP net income of $75 mln to $85 mln.Expects FY 2016 adjusted net income of $90 mln to $100 mln.Expects FY 2016 EBITDA of $150 mln to $160 mln.  Full Article

Emergent BioSolutions Inc announces plan to implement tax-free spin-off of biosciences business into a separate publicly-traded co
Thursday, 6 Aug 2015 07:01am EDT 

Emergent BioSolutions Inc:Announces plan to implement tax-free spin-off of biosciences business into a separate publicly-traded company.Board authorized co to pursue tax-free spin-off of co's biosciences business into separate, stand-alone publicly-traded co.Emergent expects to provide the biosciences company with a fixed cash contribution of $50 million to $70 million.Additional sources of cash to support research and development investment will include commercial product sales and partnership funding.Emergent to retain biodefense marketed products and development programs, platform technologies, manufacturing infrastructure.Says Emergent will maintain its headquarters in Gaithersburg, Maryland.Says expects to incur transaction-related expenses of $2 million to $4 million in 2015.Says company expects additional costs in 2016 leading up to completion of the spin-off.Says Daniel J. Abdun-nabi will remain president and CEO and robert G. Kramer will remain CFO of Emergent.Says Marvin L. white will serve as president and chief executive officer of the new biosciences company.  Full Article

BRIEF-Emergent Biosolutions gets FDA approval for large-scale manufacturing of Biothrax in building 55

* Emergent Biosolutions receives FDA approval for large-scale manufacturing of Biothrax in building 55 Source text for Eikon: Further company coverage: